FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to using melatonin orally in a prolonged-release composition for treating self-assessed non-restorative sleep in the patients suffering insomnia according to DSM-IV, wherein melatonin is the only therapeutically active agent in an amount from 0.0025 to 50 mg, and to a respective medicine for the same application.
EFFECT: melatonin has had a good effect on the sleep initiation similar to action of hypnotic agents, and shortened the sleep onset latency by 9 min on the average.
6 cl, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING SLEEP DISTURBANCES | 2008 |
|
RU2483733C2 |
| APPLICATION OF TRIPROLIDINE TO ENSURE VIVACITY IN AWAKENING | 2004 |
|
RU2372915C2 |
| USING MIRTAZAPINE FOR TREATMENT OF SLEEP DISORDER | 2001 |
|
RU2270680C2 |
| USE OF AN INVERSE AGONIST H3R FOR TREATING SLEEP DISORDER IN SHIFT WORK | 2018 |
|
RU2768894C2 |
| MELATONIN AGONIST THERAPY | 2007 |
|
RU2488392C2 |
| APPLICATION OF COMPOUND FOR TREATING SLEEP DISORDERS, FOR PROVIDING THE STATE OF CHEERFULNESS AFTER AWAKENING AND METHOD FOR TREATING THE STATE OF DEPRESSION | 2002 |
|
RU2320340C2 |
| ORGANIC COMPOUNDS | 2015 |
|
RU2785871C2 |
| ORGANIC COMPOUNDS | 2017 |
|
RU2733975C2 |
| ORGANIC COMPOUNDS | 2015 |
|
RU2728787C2 |
| PHARMACEUTICAL COMPOSITION POSSESSING SOPOROFIC EFFECT | 2004 |
|
RU2270010C2 |
